FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

FDA Abandoning Biosimilar Switching Studies

FDA issues a draft guidance indicating that it is moving away from recommending switching studies to support an interchangeability determination for b...

latest-news-card-1
Federal Register

20 No-Longer-Marketed ANDAs Withdrawn

Federal Register notice: FDA withdraws approval of 20 ANDAs from multiple applicants after they notified the agency that the drug products were no lon...

latest-news-card-1
Human Drugs

Jazz Tremor Drug Misses Primary Endpoint

Jazz Pharmaceuticals says data from its Phase 2b clinical trial evaluating the efficacy and safety of suvecaltamide in adult patients with essential t...

latest-news-card-1
Human Drugs

J&J Seeks Tremfya Crohns Indication

Johnson & Johnson asks FDA to approve a new indication for its Tremfya to treat some adults with Crohns disease.

latest-news-card-1
Medical Devices

De Novo for Onkos Implant Antibacterial Coating

FDA grants Onkos Surgical a de novo authorization for its novel antibacterial coating for use with implants.

Human Drugs

FDA OKs New Skyrizi Indication

FDA approves a new ulcerative colitis indication for AbbVies Skyrizi.

latest-news-card-1
Federal Register

Target Health ANDA Withdrawals Notice Corrected

Federal Register notice: FDA corrects a 3/29 notice on the approval withdrawals of 30 ANDAs from multiple applicants due to Target Healths notificatio...

Animal Drugs

Human User Safety in Animal Drugs Guidance

FDA publishes a guidance explaining how CVM assesses human user safety in applicable animal drug applications.

latest-news-card-1
Human Drugs

Synapse Labs Studies Unacceptable: FDA

FDA tells NDA and ANDA sponsors they must repeat clinical and bioanalytical studies conducted for their applications by Synapse Labs in Pune, India, d...

latest-news-card-1
Human Drugs

Praise, Suggestions for RWE Studies Guidance

Six stakeholders express appreciation for and suggest improvements to an FDA draft guidance on using real-world evidence in non-interventional studies...